Dracen Pharmaceuticals, Inc.
Dracen Pharmaceuticals, Inc.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, fibrolamellar hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 1 | 2026-10-05 | NCT07430202 | |
| DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, fibrolamellar hepatocellular carcinoma, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-02-12 | NCT06027086 |